# Safety and Immunogenicity of a Monovalent Inactivated Influenza H3N2 Variant (H3N2v) Vaccine in Pediatric Populations

> **NCT02100436** · PHASE2 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 270 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** Influenza Virus Vaccine, Monovalent A/H3N2v A/Minnesota/11/2010 NYMC X-203

## Key facts

- **NCT ID:** NCT02100436
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-06-11
- **Primary completion:** 2015-03-20
- **Final completion:** 2015-03-20
- **Target enrollment:** 270 (ACTUAL)
- **Last updated:** 2017-07-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02100436

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02100436, "Safety and Immunogenicity of a Monovalent Inactivated Influenza H3N2 Variant (H3N2v) Vaccine in Pediatric Populations". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT02100436. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*